Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
The 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna / Austria as a hybrid conference, allowing both in-person and virtual access
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
We are proud to present our research at ESMO Congress 2022 in Paris.
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
Please note our new address from July 18, 2022.
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
We are happy to present our research at the ASCO Annual meeting June 2022.
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
ESMO has announced that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
We are pleased to inform you that 4-year follow-up data from the BrighTNess trial has been published in Annals of Oncology.
We are pleased to inform you that a meta-analysis of capecitabine effect as part of neo-/adjuvant chemotherapy including 15,993 patients from 13 randomized trials has been published in European Journal of Cancer.